Elohes 6%: A new hydroxyethylstarch for plasma volume replacement;Un nuevo hidroxietilalmidon para la reposicion volemica: El Elohes® 6%

Revista Espanola de Anestesiologia y Reanimacion

Volumn 45, Issue 9, 1998, Pages 389-396

  Medel, J ^a   Baron, J F ^a  

^a HÔPITAL BROUSSAIS   (France)

Author keywords

Coagulation; Hemodilution; Hydroxyethylstarch; Pharmacokinetics; Plasma volume; Replacement solutions

Indexed keywords

BLOOD CLOTTING FACTOR 8; EXPAFUSIN; GELATIN; HETASTARCH; HUMAN ALBUMIN; PLASMA SUBSTITUTE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; POLYMER; POLYSTARCH; SERUM ALBUMIN; STARCH;

ANAPHYLAXIS; BLOOD CLOTTING DISORDER; COLLOID; DRUG ELIMINATION; DRUG STRUCTURE; DRUG URINE LEVEL; HEALTH CARE COST; HEMODILUTION; HUMAN; KIDNEY FUNCTION; MOLECULAR WEIGHT; PLASMA VOLUME; REVIEW; SPAIN;

HETASTARCH; HUMANS; PLASMA SUBSTITUTES; POLYMERS; SERUM ALBUMIN; STARCH;

EID: 0031736357     PISSN: 00349356     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Perret D, Bedock B, Boles JM. Choix des produits de remplissage vasculaire pour le traitement des hipovolémies chez l'adulte (4e. Conférence de consensus en réanimation et médecine d'urgence). Réan Soins Intens Méd Urg 1989; 5: 295-304.
2. Biesenbach G, Kaiser W, Zazgornik J. Incidence of acute oligoanuric renal failure in dextran 40 treated patients with acute ischemic stroke stage III or IV. Ren Fail 1997; 1: 69-75.
3. Matheson NA, Diomi P. Renal failure after the administration of dextran 40. Surg Ginecol Obstet 1970; 131: 661-668.
4. Ferraholi R, Malheiro PS, Abdulkader RC, Yu L, Sabbaga E, Burdmann EA. Anuric acute renal failure caused by dextran 40 administration. Ren Fail 1997; 19: 303-306.
5. Thomspon WL. Hydroxyethylstarch. Develop Biol Standard 1980; 44: 259-266.
6. Baron JF. Pharmacologie des hydroxythyl amidons de bas poids moléculaire. Ann Fr Anesth Réanim 1992; 11: 509-515
7. Rackow EC, Falk JL, Fein A, Siegel JS, Packman MI, Haupt MT et al. Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypvolemic and septic shock. Crit Care Med 1983; 11: 839-851.
8. Kirklin JK, Lell WA, Kouchoukus NT. Hydroxyethylstarch vs albumin for colloid infusion following cardiopulmonary bypass in patients undergoing myocardial revascularization. Ann Thorac Surg 1984; 37: 40-46.
9. Moggio RA, Rha CC, Somberg ED, Praeger PI, Pooley RW, Reed GE. Hemodynamic comparison of albumin and hydroxyethiylstarch in postoperative cardiac surgery patients. Crit Care Med 1983; 11: 943-945.
10. Diehl JT, Lester JL, Cosgrove DM. Clinical comparison of hetastarch and albumin in postoperative cardiac patients. Ann Thorac Surg 1982; 34: 674-679.
11. London MJ, Ho JS, Triedman JK, Verrier ED, Levin J, Merrick SH. A randomized clinical trial of 10% pentastarch (low molecular weight hydroxyethylstarch) versus 5% albumin for plasma volume expansion after cardiac operations. J Thorac Cardiovasc Surg 1989; 97: 785-797.
12. Quon CY. Clinical pharmacokinetics and pharmacodynamics of colloidal plasma volume expanders. J Cardiothorac Anesth 1988; 2: 13-23.
13. Korttila K, Grohn P, Gordin A, Sundberg. Salo H, Nissinen E et al. Effect of hydroxyethylstarch and dextran on plasma volume and blood hemostasis and coagulation. J Clin Pharmacol 1984; 24: 273-282.
14. Baron JF Low molecular weight Hydroxyethyl starches. En: Plasma volume expansion. París: Arnette Blackwell, 1992; 121-132.
15. Mishler JM, Ricketts CR, Parkhouse EJ. Postinfusion survival of hydroxyethylstarch 450/0,7 in man: a long-term study. J Clin Pathol 1980; 33: 155-159.
16. Ferber HP, Nitsch E, Förster H. Studies on hydroxyethylstarch. Part II. Changes of the molecular weight distribution of hydroxyethylstarch types 450/0,7, 450/0,5, 450/0,3, 300/0,4, 200/0,7, 200/0,5, 200/0,3 and 200/0,1 after infusion in urine and serum of volunteers. Arzneim-Forsch/Drug Res 1985; 35: 615-622.
17. Degrémont AC, Ismail M, Arthaud M, Oulare B, Mundler O, Paris M et al. Mechanisms of postoperative prolonged plasma volume expansion with low molecular weight hydroxyethylstarch (HES 200/0,62 6%). Intensive Care Med 1995; 21: 577-583.
18. Hulse JD, Yacobi A, Hetastarch an overview of the colloid and its metabolism. Drug Intel Clin Pharm 1983; 17: 334-340.
19. Guidet B, Podevin P, Robert A, Chauvin P, Maury E, Offenstadt. High doses of hydroxyethyl starch and human albumin have similar effects on monocyte function and oncotic pressure. Eur J Clin Invest 1997; 27: 943-947.
20. Treib J, Haass A, Pindur G, Grauer A, Wenzel B, Schimrigk K. Decrease of fibronectin following repeated infusion of highly substituted hydroxyethyl starch. Infusionsther Transfusionsmed 1996; 23: 71-75.
21. Metcalf M, Papadoulos A, Tufaro R, Barth A. A clinical phisyologic study of hydroxyethylstarch. Surg Gynecol Obstet 1970; 131: 255-267.
22. Yacobi A, Stoll RG, Sum CY. Pharmacokinetics of hydroxyethylstarch in normal subjects. J Clin Pharmacol 1982; 22: 206-212.
23. Maguire LC, Strauss RG, Koepke JA. The elimination of hydroxyethylstarch from the blood of donors experiencing single or multiple intermittent flow centrifugation leukapheris. Transfusion 1981; 21: 347-353.
24. Boon JC, Jesch F, Ring J, Messmer K. Intravascular persistence of hydrixyethylstarch in man. Eur Surg Res 1976; 8: 497-503.
25. Mishler JM, Parry ES, Petrie A. Plasma clearance and renal excretion of erytrocyte cryoprotectant hydroxyethylated amylopectin. Br J Haematol 1978; 40: 231-237.
26. Mishler JM, Parry ES. Transfusion of hydroxyethyllated amylopectin-protected frozen blood in man. Vox Sang 1979; 36: 337-341.
27. Köhler H, Zschiedrich H, Linfante A, Appelf, Ptiz H, Clasen R. Elimination of hydroxyethylstarch 200/0,5, dextran 40 y oxypolygelatin. Klin Wochenschr 1982; 60: 293-301.
28. Mishler JM, Parry ES, Sutherland BA, Bushrod JR. A clinical study of low molecular weight-hydroxyethylstarch, a new plasma expander. Br J Clin Pharmacol 1979; 7: 619-622.
29. Köhler H, Zschiedrich H, Clasen R, Linfante A, Gamm H. Blood volume, colloid osmotic pressure and kidney function after infusion of 10% medium molecular weight hydroxyethylstarch 200/0,5 and 10% dextran 40 in human volunteers. Anaesthesist 1975; 24: 193-197.
30. Treib J, Hass A, Pindur G. Coagulation disorders caused by hydroxyethyl starch. Thromb Haemost 1997; 78: 974-983.
31. Rackow EC, Mecher C, Astiz ME, Griffel M, Falk JL. Weil H. Effects of pentastarch and albumin infusion on cardiorespiratory function and coagulation in patients with severe sepsis and systemic hypoperfusion. Crit Care Med 1989; 17: 396-398.
32. Waxman K, Holnass R, Tominaga G, Chela P, Gimes J. Hemodynamic and oxygen transport effects of pentastarch in burn resuscitation. Ann Surg 1989; 209: 341-345.
33. Strauss RG, Stansfield C, Henriksen RA, Villhauer PJ. Pentastarch may cause fewer effects on coagulation than hetstarch. Transfusion 1988; 28: 257-260.
34. Iguchi K, Ikeda K. Clinical investigation of a new plasma expander partially substituted HES. Med Concul N Remed 1971; 8: 139-150.
35. Baron JF, De Kegel D, Prost AC, Mundler O, Arthaud M, Basset G. Low molecular weight hydroxyethyl starch 6% compared to albumin 4% during intentional hemodilution. Intens Care Med 1991; 17: 141-148.
36. Baron JF, De Kegel D, Prost AC, Mundler O, Maistre G, Carayon A et al. Hemodynamic and hormonal effects of normovolemic hemodilution using hydroxyethyl starch. Clin Intens Care 1991; 2: 22-26.
37. Laxenaire MC, Charpentier C, Feldman I. Anaphilactoid reactions to colloid plasma substitutes: incidence, risk factors, mechanisms. A french multicenter prospective study. Ann Fr Anesth Reanim 1994; 13: 301-310.
38. Boldt J, Muller M, Mentges D, Papsdorf M, Hempelmann G. Influence of different volume therapy regime on regulations of circulation in critically ill. Br J Anaesth 1996; 77: 480-487.
39. Boldt J, Müller M, Heesen M, Martin K, Hempelmann G. Influence of different volume therapies and pentoxifylline infusion on circulating soluble adhesion molecules in critically ill patients. Crit Care Med 1996: 24: 385-391.
40. Messmer K, Jesch F. Voluemnersatz and haemodilution durch hydroxyaethylstaerke. Infusiontherapie 1978; 5: 169-177.
41. Stump DC, Strauss RG, Henriksen RA, Petersen RE, Saunders R. Effects of hydroxyethyl starch on blood coagulation, particulary F VIII. Transfusion 1985; 25: 349-354.
42. Macintyre E, Mackcie IJ, Ho D, Tinker J, Bullen C, Machin ST. The haemostatic effets of hydroxyethyl starch (HES) used as a volume expanded. Intens Care Med 1985: 11: 300-303.
43. Dalrymple HM, Aitchison R, Collins P, Sekhar M, Calvin B. Hydroxyethyl starch induced acquired von Willebrand's disease. Clin La Haematol 1992; 14: 209-211.
44. Penner M, Fingerhut D, Tacke A. Effect of a new 10% hydroxyethyl starch solution HES 270/0,5 on blood coagulation, blood loss and hemodynamics in comparison with 3,5 PPL. Infusiontherapie 1990; 17: 314-318.
45. Van den Brink WA, Van Genderen P, Thiijsse WJ, Michiels JJ. Hetastarch coagulopathy. J Neurosurg 1996; 85: 367.
46. Treib J, Haass A, Pindur G, Miyachita C, Grauer MT, Jung F et al. Highly substituted hydroxyethyl starch (HES 200/0,62) leads to a type I von Willebrand syndrome after repeteaded administration. Haemostasis 1996; 26: 210-213.
47. Sanfelippo MJ, Suberviola PD, Geimer NF. Development of a von Willebrand-Like syndrome after prolonged use of hydroxyethyl starch. Am J Clin Pharmacol 1987; 88: 653-655.
48. Lockwood DNJ, Bullen C, Machin SJ. A severe coagulopathy following volume replacement with hydroxyethyl starch in Jehova's witness. Anaesthesia 1988; 43: 391-393.
49. Trumble ER, Muizelaar JP, Myseros JS, Choi SC, Warren BB. Coagulopathy with the use of hetastarch in the treatment of vasospasm. J Neurosurg 1995; 82: 44-47.
50. Treib J, Haass A, Pindur G, Seyfert UT, Treib W, Grauer MT et al. HES 200/0,5 is not HES 200/0,5. Influence of the C2/C6 hydroxyethylation rati of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. Thromb Haemost 1995; 74: 1.452-1.456.
51. Treib J, Haass A, Pindur G, Gruaer MT, Wenzel E, Schimrigk K. All meidum starches are not the same. Influence of degree of substitution of hydroxyethylstarch on plasma volume, hemorheologic conditions, and coagulation. Transfusion 1996; 36: 450-455.
52. Treib J, Haass A, Pindur G, Grauer MT, Seyfert UT, Treib W, Wenzel E et al. Influence of low molecular weight hydroxyethyl starch on hemostasis and hemorheology. Haemostasis 1996; 26: 258-265.
53. Treib J, Haass A, Pindur G, Grauer MT, Treib W, Wenzel E et al. Increased hemorrhagic risk after repeated infusion of highly substituted medium molecular weight hydroxyethylstarch. Arzneim Forsch/Drug Res 1997; 47: 18-22.
54. Treib J, Haass A, Pindur G, Miyachita C, Grauer MT, Jung F et al. Highly substituted hydroxyethyl starch (HES 200/0,62) leads to a type I von Willebrand syndrome after repeated administration. Haemostasis 1996: 26: 210-213.
55. Kiiesewetter H, Waldhausen P, Schimetta W, Wilhelm HJ, Koscielny J. En: Hemodilution. New aspects in the management of circulatory blood flow. Improvement of macro- and microcirculation. Berlín, Heilderberg, Nueva York: Springer Verlag, 1992: 165-170.
56. Szcpfalusi Z, Parth E, Jurccka W, Luger TA, Kraft D. Human monocytes and keratinocytes in culture ingest hydroxyethyl starch. Arch Dermatol Res 1993; 285: 144-150.
57. Thompson WL, Fukushima F, Rutherford RB, Walton RP. Intravasale persistenz, gewebsspeicherung and ausscheidung von hydroxyaethylstaerke (HAES). Infusiontherapie 1979; 6: 151-155.
58. Legendre C, Thervet E, Page B, Percheron A, Nöel LH, Kreis H. Hydroxyethyl starch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 1993; 342: 248-249.
59. Cittanova M, Leblanc I, Legendre Ch, Mouquet C, Riou B, Coriat P. Effect of the hydroethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996; 348: 1.620-1.622.
60. Coronel B, Mercatello A, Martin X, Lefrancois N. Hydroxyethyl starch and renal function in kidney transplant recipients [carta]. Lancet 1997; 349: 884.
61. Vogt NH, Bothner U, Lerch G, Lindner KH, Georgieff M. Large-dose administration of 6% hydroxyethyl starch 200/0,5 for total hip arthroplasty: plasma homeostasis, hemostasis, and renal function compared to use of 5% human albumin. Anesth Analg 1996; 83: 262-268.
62. Godet G, Fléron ME, Vicaut E, Zubicki A, Bertrand M, Riou B et al. Risk factors for acute postoperative renal failure in thoracic or thoracoabdominal aortic surgery: a prospective study. Anesth Analg 1997; 85: 1.227-1.232.
63. Moran M, Kapsner C. Acute renal failure associated with elevated plasma oncotic pressure. N Engl J Med 1987; 317: 150-153.
64. Ferraboli R, Malheiro PS, Abdulkader RC, Yu L, Sabbaga E, Burdmann EA. Anuric acute renal failure caused by dextran 40 administration. Ren Fail 1997; 19: 303-306.
65. Waldhausen P, Kiesewetter H, Leipnitz G, Scielny J, Jung F, Bambauer R et al. Hydroxyethyl starch-induced transient renal failure in preexisting gromerular damage. Acta Med Austriaca 1991; 1: 52-55.
66. Hussain SF, Drew PJ. Acute renal failure after infusion of gelatins. BMJ 1989; 299: 1.137-1.138.
67. Rozich JD, Paul RV. Acute renal failure precipitated by elevated colloid osmotic pressure. Am J Med 1989; 87: 359-360.
68. Haskell LP, Tannenberg AM. Elevated urinary specific gravity in acute oliguric renal failure due to hetastarch administration. N Y State Med 1988; 88: 387-388.